

MEDICAID MANAGED CARE AND PRESCRIPTION DRUG PRICES

Posted by Robert Kaestner

Posted on 1/20/2021 2:17 PM

Comment on A Dose of Managed Care: Controlling Drug Spending in Medicaid, By David Dranove, Christopher Ody, and Amanda Starc

In this comment, I re-estimate some of the models presented in Dranove et al. (2021) to show the sensitivity of estimates to a couple of regression model specification choices, and I conduct a different analysis that seems conceptually important, but which was omitted from Dranove et al. (2021). In both analyses, I focus on the point-of-sales price of prescription drugs and how that price varies between Medicaid managed care organizations (MCO) and public, fee-for-service (FFS) purchase.

Go to the link below to see results and interpretation.

Comment on A Dose of Managed Care: Controlling Drug Spending in Medicaid, By David Dranove, Christopher Ody, and Amanda Starc